j Abstract Objective Familial dysautonomia (FD) involves incomplete development of the sympathetic nervous system. Whether such loss extends to sympathetic innervation of the heart has been unknown. This study used 6-[ pre-treatment by desipramine, which interferes with neuronal uptake and thereby simulates effects of noradrenergic denervation. Effective rate constants for uptake and loss were calculated using a single compartment pharmacokinetic model. Results FD patients had decreased uptake and accelerated loss of 6-[ 18 F]fluorodopamine-derived radioactivity in the interventricular myocardial septum (P = 0.009, P = 0.05) and ventricular free wall (P = 0.007, P < 0.001), compared to untreated controls. Desipramine-treated subjects had decreased uptake but normal loss of 6-[ ]fluorodopamine-derived radioactivity cannot be explained by decreased neuronal uptake alone, FD may also involve augmented NE loss from extant terminals.
j Key words familial dysautonomia AE fluorodopamine AE sympathetic nervous system AE positron emission tomography AE norepinephrine sion without compensatory tachycardia, episodic hyperhidrosis, gastroesophageal reflux, and decreased tear production. Central neural abnormalities include emotional lability and susceptibility to crises of vomiting, tachycardia, and paroxysmal hypertension. Other findings include oral incoordination, kyphoscoliosis, no axon flare reaction after intracutaneous histamine injection, and absence of fungiform lingual papillae. With supportive treatment, prognosis has improved greatly, so that about 40% of surviving patients are over age 20 years [2] .
Adult patients with FD typically have orthostatic hypotension, associated with deficient orthostatic increments in plasma levels of the sympathetic neurotransmitter, norepinephrine (NE) [24] . Studies in the 1960s and 1970s noted relatively increased production of dopamine and its metabolites compared to NE and its metabolites [12, 21] , consistent with decreased activity of dopamine-beta-hydroxylase, the enzyme catalyzing conversion of dopamine to NE. Plasma levels of dopamine-beta-hydroxylase activity initially were found to be decreased [23] , but a subsequent report failed to confirm this finding [4] .
Outside the brain, dopamine-beta-hydroxylase is localized to vesicles in sympathetic neurons and chromaffin cells. Post-mortem or biopsy studies have indicated that, rather than autonomic failure in FD reflecting dopamine-beta-hydroxylase deficiency, FD entails decreased numbers of sympathetic neurons. Blood vessels in renal and sural nerve biopsy tissue from FD patients have reduced sympathetic terminals [15, 16] , and sympathetic ganglia contain decreased numbers of neurons [17] .
The heart normally possesses abundant sympathetic innervation; however, neuropathological investigations have not been performed of this critical network in FD patients, a patient population known to have an increased incidence of sudden death [2] . 6-[ 18 F]Fluorodopamine positron emission tomographic (PET) scanning can visualize cardiac sympathetic innervation [7] in vivo and may provide insights about the functional status of sympathetic nerves [10, 11] .
In this study we carried out 6-[
18 F]fluorodopamine PET scanning in adult patients with FD and compared the results to those in healthy age-matched controls. Some control subjects were pretreated with desipramine, a tricyclic antidepressant that inhibits catecholamine uptake by sympathetic nerves via the cell membrane NE transporter and thereby simulates decreased transporter activity due to denervation. We hypothesized that FD patients would have decreased density of sympathetic nerves in the myocardium that could be demonstrated by decreased uptake of 6-[ 
Methods
Six adult patients with FD (mean age 33 ± 4 (SEM) years, 2 males 4 females) underwent thoracic positron emission tomographic (PET) scanning for 30 minutes after i.v. injection of 6-[ 18 F]fluorodopamine at the NIH Clinical Center. All the patients had been diagnosed at and were followed by the Familial Dysautonomia Clinic of the New York University Medical Center. All the patients were tested while on their usual medications. None was taking any medication known to affect the neuronal uptake of catecholamines.
Thoracic PET scanning was conducted as described previously [7] . Briefly, 6-[ 18 F]fluorodopamine (1 mCi) was injected i.v. over 3 minutes using an automated syringe pump. Dynamic 3-D data were acquired for 30 minutes from the time of initiation of the injection. Regions of interest were placed in the interventricular septum, apex, and free wall, and time-activity curves were generated from the average radioactivity in each region of interest. Radioactivity (in nCi/ cc) was adjusted for the 6-[ 18 F]fluorodopamine dose per unit body mass (mCi/kg) and therefore expressed in units of nCi-kg/cc-mCi. There were 9 scanning frames, with the midpoints at about 0.5, 1.5, 2.5, 3.5, 8, 13, 18, and 26 minutes from the start of injection.
In each subject, a mono-exponential curve of best fit was generated for the concentrations of 6-[ 18 F]fluorodopamine-derived radioactivity in the septum and left ventricular free wall, at the time of peak radioactivity (usually in the 8 minute frame). The yintercept (y 0 ) value was taken as an index of the uptake of 6-[ 18 F]fluorodopamine by sympathetic nerves, and the rate constant for loss of radioactivity (k loss ) was taken as an index of rapid exchange between the vesicles and extracellular fluid [11] .
The neuroimaging data in the FD group were compared with those in a previously studied group of untreated healthy volunteers (N = 21, mean age 31 ± 1 years, 16 males 5 females) and in a previously studied group of healthy volunteers (N = 10, mean age 42 + 3 years, 9 males 1 female) who were pre-treated with oral desipramine about 1.5-2 hours before 6-[ Mean values were compared between the FD and control group and between the desipramine-treated and untreated groups by independent-means t tests. All mean values were expressed ± SEM.
Results

FD patients had diffusely decreased 6-[
18 F]fluorodopamine-derived radioactivity throughout the left ventricular myocardium or had heterogeneously decreased radioactivity, with greater loss in the apex or inferolateral free wall than in the anterobasal septum (Figure 1 ).
Time-activity curves for myocardial 6-[
18 F]fluorodopamine-derived radioactivity indicated decreased uptake in the FD group, compared to the untreated control group, and accelerated loss compared to both treated and untreated control groups (Figure 2) . When compared to untreated controls, FD patients had decreased uptake of 6-[ 18 F]fluorodopamine, as reflected by a low mean value for y 0 , in both the septum (7,952 ± 1,054 vs. 10,792 ± 423 nCi-kg/ccmCi in untreated controls, P = 0.009) and free wall (6,985 ± 900 vs. 10,151 ± 487 nCi-kg/cc-mCi in untreated controls, P = 0.007); however, the decrease in uptake was not as marked as in the desipramine-treated subjects as the curve relating myocardial 6-[ 18 F]fluorodopamine-derived radioactivity with time (time-activity curve) was displaced downward compared to that in FD patients and the untreated control subjects (Figure 2) . In neither the FD patient group nor the untreated control group did the mean value for y 0 differ between the septum and free wall. Desipramine-treated subjects, had a low mean value for y 0 in the septum (5,850 ± 586 nCi-kg/cc-mCi, P < 0.001 compared to untreated subjects).
Time-activity curves also indicated that the FD group had accelerated loss of 6-[ 0.020 ± 0.001 min )1 in untreated controls, P = 0.05) and free wall (0.029 ± 0.002 vs. 0.018 ± 0.001 min )1 in untreated controls, P < 0.001). Desipramine-treated subjects had about the same mean value for k loss (0.022 ± 0.003 min )1 ) as in untreated control subjects.
Discussion
The present neuroimaging findings provide in vivo neuroimaging evidence that FD involves decreased cardiac sympathetic innervation. Previous studies described diminished sympathetic neuronal populations in biopsies of renal blood vessels and sural nerve [15, 16] , and decreased numbers of neurons in sympathetic ganglia harvested post-mortem. Note decreased radioactivity in FD at all time points, compared to untreated control subjects, with more rapid decline in radioactivity in the FD group compared to both untreated and desipramine-treated control subjects Consistent with decreased numbers of cardiac sympathetic neurons, at all time points after injection of the sympathetic neuroimaging agent (6-[ ]fluorodopamine-derived radioactivity were decreased by about 25% in the interventricular septum and about 30% in the left ventricular free wall, compared to values in untreated control subjects. These percent decreases were smaller than those found in healthy volunteers pre-treated with desipramine (about 45% in the interventricular septum). FD, therefore, may entail a quantitative decrease in the density of cardiac sympathetic nerves, rather than a complete absence of innervation; although two of the six patients did have markedly decreased 6-[ ]fluorodopamine-derived radioactivity in the myocardium reflects uptake by sympathetic nerves, since destruction of those nerves, by 6-hydroxydopamine injection, results in inability to distinguish radioactivity in the myocardium from that in the left ventricular chamber [8] . Moreover, intra-neuronal 6-[ Either of these in vivo functional changes would fit with previous post-mortem reports demonstrating increased tyrosine hydroxylase immunoreactivity in sympathetic ganglia of patients with FD [14] , despite decreased numbers of ganglionic neurons [17] . Although decreased urinary excretion of radiolabeled NE and its metabolites after administration of 14 Cdopamine was taken as indicating decreased NE synthesis [12] , this finding could be explained by sympathetic hypo-innervation or by decreased vesicular uptake of dopamine. In Parkinson disease, which also entails a decrease in cardiac sympathetic innervation [9] , there is increased washout of 123 Imetaiodobenzylguanidine-derived radioactivity [13, 22] , consistent with a functional change analogous to that noted here in FD patients.
123
I-Metaiodobenzylguanidine is not a substrate for monoamine oxidase. Assuming that the same functional change occurs in FD as in PD, the available evidence would seem to favor compensatorily increased exocytosis over decreased vesicular sequestration as the mechanism of accelerated loss of 6-[ Patients with FD seem to have an increased risk of tachy-and brady-arrhythmias, asystole, and sudden death [5, 6, 18] . Our finding of cardiac hypoinnervation provides a possible explanation for arrythmias in FD. A developmental abnormality of cardiac sympathetic innervation, involving areas with approximately normal innervation nearby areas without innervation, could set the stage for re-entry type tachy-arrhythmias from heterogeneous conduction or heart block or asystole from unopposed vagal tone.
FD is thought to be a progressive disorder. Whether preadolescent patients would have the same degree of hypo-innervation as adults remains unknown; however, since there was essentially no difference between the findings in a 21-and a 50-year-old patient in our study, the hypo-innervation may be mainly a developmental problem.
With recent decriptions of in vitro agents that can rescue the mRNA IKBKAP splicing defect and enhance levels of functional ELP-1 in FD cell lines [20] , pathophysiology-based treatment of this disease may evolve out of future clinical trials. The present findings suggest that in vivo cardiac neuroimaging, along with neurochemical profiles, may be biomarkers with which to track effects of treatment.
